Lung adenocarcinoma promotion by air pollutants
The Francis Crick Institute · Cancer Research UK · +86 more institutions
Abstract
A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development1. Here we propose that environmental particulate matter measuring ≤2.5 μm (PM2.5), known to be associated with lung cancer risk, promotes lung cancer by acting on cells that harbour pre-existing oncogenic mutations in healthy lung tissue. Focusing on EGFR-driven lung cancer, which is more common in never-smokers or light smokers, we found a significant association between PM2.5 levels and the incidence of…
Citation impact
- FWCI
- 110.19
- Percentile
- 100%
- References
- 77
Authors
326- WHWilliam Hill
The Francis Crick Institute
- ELEmilia L. Lim
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- CEClare E. Weeden
The Francis Crick Institute
- CLClaudia Lee
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- MAMarcellus Augustine
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
Topics & keywords
- Lung cancer
- KRAS
- Carcinogenesis
- Cancer research
- Lung
- Adenocarcinoma
- Medicine
- Carcinogen
- Good health and well-being
Funding
- AAAmerican Association for Cancer ResearchAward: 18-90-52-DEGR
- BCBreast Cancer Research Foundation
- LFLUNGevity Foundation
- AAmgen
- BSBristol-Myers Squibb
- PPfizer
- AAstraZeneca
- IAInternational Association for the Study of Lung Cancer
- EIEntertainment Industry Foundation
- EREuropean Respiratory Society
- WTWellcome TrustAwards: FC001169, FP7/2007-2013, FC001112, 211179/Z/18/Z
- FCFrancis Crick InstituteAwards: FC001112, FC001169
- LLifeArc
- GQGénome Québec
- APAstex Pharmaceuticals
- RMRevolution Medicines
- IInvitae
- CRCancer Research UKAwards: FP7/2007-2013, ID16584, SEBSTF-2021\100007, FC001169, C69256/A30194, FC001112
- NINational Institute for Health and Care ResearchAward: FP7/2007-2013
- UCUniversity College London
- ECEuropean CommissionAwards: 665233, FP7/2007-2013, H2020, 2007-2013, FP7/2007, 725492, 607722, 835297, 617844
- RTRosetrees TrustAwards: ID16584, A2437
- NRNational Research Foundation
- NNNational Natural Science Foundation of ChinaAwards: FP7/2007-2013, FP7/2007, 82072566
- CCancerfonden
- KHKorea Health Industry Development InstituteAward: HR20C0025
- NRNational Research Foundation of KoreaAward: 2020R1A2C3006535
- VVetenskapsrådetAward: FP7/2007-2013
- CGChang Gung Medical Foundation
- CAChinese Academy of Medical SciencesAward: 2021RU002
- PUPeking University
- UCUniversity College London Hospitals NHS Foundation Trust
- OPOno Pharmaceutical
- MOMinistry of Science and ICT, South Korea
- PUPeking University People's HospitalAward: RS2019-01
- NINational Institutes of HealthAwards: P30CA046934, FP7/2007-2013, T32CA174648, CA219893, H2020, T32-CA190216
- GGenentech
- SUStand Up To CancerAwards: SU2C-AACR-DT23-17, AACR-DT23-17
- H2Horizon 2020 Framework ProgrammeAwards: FP7/2007-2013, 665233, 835297
- MRMedical Research CouncilAwards: MR/P014712/1, MR/V033077/1, FC001112, MR/W025051/1, MR/V033077/1, MR/P014712/1, FC001169
- JSJapan Society for the Promotion of ScienceAward: 052004
- NCNational Cancer InstituteAwards: P30CA046934, T32-CA190216, CA190216, T32CA174648
- LCLinda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Anschutz Medical Campus